CD8+ T cell tolerance and cancer immunotherapy

被引:45
作者
de Visser, KE [1 ]
Schumacher, TNM [1 ]
Kruisbeek, AM [1 ]
机构
[1] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
关键词
cancer immunotherapy; CD8(+) T cell tolerance;
D O I
10.1097/00002371-200301000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To provide protection against all foreign pathogens one can possibly encounter during their lifetime, the T cell repertoire has to be as diverse as possible. At the same time, it is desirable that the T cell repertoire remains unresponsive towards healthy tissues. To realize this self/nonself discriminatory property, T cells undergo tightly controlled selection processes during maturation in the thymus. The key parameter determining the outcome of these selection processes is the avidity of the T cells for self-MHC/self-peptide complexes expressed in the thymus; low avidity interactions result in positive selection, whereas high avidity interactions lead to negative selection. Despite the selection processes, self-tolerance is far from absolute. In many cases, this is due to the presence of self-antigen in the thymus at a level that is too low to induce thymic deletion. In addition, T cells with a low avidity for ubiquitously expressed self-antigens can escape clonal deletion and enter the periphery. A thorough understanding of the self-specific T cell repertoire is important because many potential targets for cancer immunotherapy are self-proteins. In this review, the authors discuss the impact of self-antigen expression on the CD8(+) T cell repertoire. An overview of the fate and functional capacities of self-specific T cells with specificity for tissue-restricted self-antigens and for ubiquitously expressed self-antigens is provided. Furthermore, the authors discuss the influence of negative selection on the antitumor reactivity of the mature T cell repertoire. Key Words: Cancer immunotherapy-CD8(+) T cell tolerance.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 134 条
[1]   Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer [J].
Adams, M ;
Borysiewicz, L ;
Fiander, A ;
Man, S ;
Jasani, B ;
Navabi, H ;
Lipetz, C ;
Evans, AS ;
Mason, M .
VACCINE, 2001, 19 (17-19) :2549-2556
[2]   T-cell-receptor affinity and thymocyte positive selection [J].
Alam, SM ;
Travers, PJ ;
Wung, JL ;
Nasholds, W ;
Redpath, S ;
Jameson, SC ;
Gascoigne, NRJ .
NATURE, 1996, 381 (6583) :616-620
[3]   Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy [J].
AlexanderMiller, MA ;
Leggatt, GR ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4102-4107
[4]   LONG-LIFE SPAN OF TOLERANT T-CELLS AND THE ROLE OF ANTIGEN IN MAINTENANCE OF PERIPHERAL TOLERANCE [J].
ALFERINK, J ;
SCHITTEK, B ;
SCHONRICH, G ;
HAMMERLING, GJ ;
ARNOLD, B .
INTERNATIONAL IMMUNOLOGY, 1995, 7 (02) :331-336
[5]  
ALRAMADI BK, 1995, J IMMUNOL, V155, P662
[6]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[7]   Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling [J].
Baker, BM ;
Gagnon, SJ ;
Biddison, WE ;
Wiley, DC .
IMMUNITY, 2000, 13 (04) :475-484
[8]   MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100 IS RECOGNIZED BY MELANOMA-DERIVED TUMOR-INFILTRATING LYMPHOCYTES [J].
BAKKER, ABH ;
SCHREURS, MWJ ;
DEBOER, AJ ;
KAWAKAMI, Y ;
ROSENBERG, SA ;
ADEMA, GJ ;
FIGDOR, CG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :1005-1009
[9]   Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? [J].
Benoist, C ;
Mathis, D .
NATURE IMMUNOLOGY, 2001, 2 (09) :797-801
[10]   REVERSAL OF INVITRO T-CELL CLONAL ANERGY BY IL-2 STIMULATION [J].
BEVERLY, B ;
KANG, SM ;
LENARDO, MJ ;
SCHWARTZ, RH .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (06) :661-671